Receptor Discordance: Does it Mean Anything?
- 1 December 2010
- journal article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 10 (6), 419-420
- https://doi.org/10.3816/cbc.2010.n.066
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and MetastasisThe Oncologist, 2010
- Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine ResistanceClinical Cancer Research, 2010
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Discordance between Receptor Status in Primary and Metastatic Breast Cancer: an Exploratory Study of Bone and Bone Marrow BiopsiesClinical Oncology, 2008
- Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient ManagementThe Oncologist, 2008
- Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein KinaseJournal of Clinical Oncology, 2005
- Gene expression profiles of primary breast tumors maintained in distant metastasesProceedings of the National Academy of Sciences of the United States of America, 2003
- Minimum Formalin Fixation Time for Consistent Estrogen Receptor Immunohistochemical Staining of Invasive Breast CarcinomaAmerican Journal of Clinical Pathology, 2003